Industry Expert Panel Weighs CNPV Benefits, Risks, and Readiness: Part I

Editor’s Note: Opinions expressed herein do not necessarily reflect those of the firms/companies for which the speakers work.
Check out additional coverage and industry expert perspectives in “The Regulatory Crucible: Risk, Resource Drain, and the Hidden Trade-Offs of the CNPV Pilot Program” and “Ready or Not: Biopharma Alignment for CNPV’s Rapid Review.”

And check out “How the FDA Commissioner’s National Priority Vouchers Reshape Manufacturing, Pricing & Global Strategy,” as well as “Winners & Losers: What the First FDA Commissioner’s National Priority Vouchers Tell Us About Early Movers vs. Late Movers” from our colleagues over at…